Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-16 · accession 0000899243-22-029046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-17 | 2022-08-16 | KLRS | Brainard Diana | CEO, Dir | A - Grant | $0.00 | +100.0K | 642.1K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-16 | A | A | 100,000 | $0.00 | 642,112 | D | — | — | (F1) The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter. |